Global pharma and healthcare are now going through a complex and multidimensional transformation – distinct boundaries between the sectors are disappearing as the industry becomes a more integrated system. This is a consequence of such major industry-changing trends as technological and scientific innovation, a new patient-centric focus, and the evolving government regulations – all of which increasingly influence industry players.
Only a firm which truly knows this field from practical experience can provide appropriate legal advice and help navigate all the complexities presented today. We are committed to fully understanding the sector peculiarities and business needs as well as to developing and implementing the most effective strategies to keep our clients ahead of the curve.
We provide expert advice and assistance in matters involving various antitrust issues, in particular, in clearing mergers and horizontal arrangements, advising on R&D and cooperation agreements, streamlining pricing, marketing, advertising and other commercial practices, as well as in advising on unfair competition matters. We further assist in corporate, labour & employment, and intellectual property, in particular, in data protection, issues.
We are proud to list some of the major pharmaceuticals and cosmetics manufacturers as being among our clients.
We advise major corporations on a wide range of legal matters:
Sanofi in obtaining merger clearance for a high profile swap operation of its 11.4 billion EUR Animal Health business (Merial) for Boehringer Ingelheim’s Consumer Health Care business estimated at 6.7 billion EUR;
L'Oreal on the 1.15 billion EUR acquisition of YSL Beaute Holding;
GlaxoSmithKline on a 3.6 billion USD acquisition of control over the dermatological pharmaceuticals manufacturer Stiefel and on various issues, including pharmaceutical and consumer protection matters, pertaining to the operation of GSK subsidiaries in Ukraine;
Teva Pharmaceutical Industries in obtaining merger and antitrust clearance for transactions with Allergan, Barr, Cephalon, Procter & Gamble, and ratiopharm;
Sanofi-Aventis on their 2.6 billion USD acquisition of shares in Zentiva;
Beiersdorf Ukraine on a range of tax, unfair competition, and employment law matters, trademark registration, and licensing;
Daiichi Sankyo Company Limited in connection with obtaining approval from the competition authority for the 4.6 billion USD acquisition of a controlling block of shares in Ranbaxy Laboratories Limited;
Ecolab, a leading provider of cleaning, food safety, and health protection products and services, on trademark registration and license agreements;
Novartis, a Swiss-based global pharmaceuticals manufacturer, in obtaining clearance from the competition authority for their 28.1 billion USD acquisition of a majority stake in Alcon, a global leader in eye care, from Nestlé S.A.;
Sopharma AD (Bulgaria) on their acquisition of a majority stake in Vitaminy, a Ukrainian pharmaceutical factory, and on various matters, including corporate, compliance, obtaining a license for pharmaceutical production, and on complex contract and trademark litigation with one of their distributors;
Heel, one of Europe's leading pharmaceutical companies, on a range of matters, including sales and distribution, as well as protection from unfair competition;
Fapomed SA, a Portuguese producer of medical equipment, in a project involving the engineering and construction of a factory in Ukraine;
Schering-Plough and Merck in obtaining AMC clearance for their 41.1 billion USD merger resulting in the creation of the second-largest pharmaceutical company in the world.
In addition to our expertise in these general matters, we are well known for our innovative solutions to complex legal problems, e.g., the legal regulation of clinical testing.